Anifrolumab
Anifrolumab
Anifrolumab (pronounced as an-i-fro-lu-mab) is a monoclonal antibody designed for the treatment of autoimmune diseases. It is specifically developed to inhibit the type I interferon receptor, thus blocking the activity of all subtypes of interferon alpha, beta, omega, and others.
Etymology
The name Anifrolumab is derived from the words 'ani-' (against), 'fro-' (interferon alpha receptor), and '-lumab' (human monoclonal antibody).
Mechanism of Action
Anifrolumab works by binding to the subunit 1 of the type I interferon receptor, inhibiting the activity of type I interferons. These interferons are proteins produced by the body's immune cells in response to viral infections, but in autoimmune diseases, they can be overproduced, leading to inflammation and tissue damage.
Clinical Uses
Anifrolumab has been studied for use in several autoimmune diseases, including systemic lupus erythematosus (SLE) and Sjögren's syndrome. In 2020, it was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with moderate to severe SLE who are receiving standard therapy.
Related Terms
External links
- Medical encyclopedia article on Anifrolumab
- Wikipedia's article - Anifrolumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski